Corteva, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Corteva, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.40B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $16.91B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $17.23B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $17.46B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $15.66B | Feb 8, 2024 |
| FY2020 | Dec 31, 2020 | $3.21B | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $1.86B | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $5.19B | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $3.96B | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $2.98B | Feb 11, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $907.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $735.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.15B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.76B | Feb 8, 2024 |
| FY2020 | Dec 31, 2020 | $41.00M | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | ($392.00M) | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $760.00M | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $272.00M | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | ($21.00M) | Feb 11, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.47B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.40B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.34B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.22B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.19B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $1.14B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $1.15B | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $1.36B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $484.00M | Feb 14, 2020 |
| FY2019 | Aug 31, 2017 | $591.00M | Feb 14, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.49B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.20B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $3.18B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $3.17B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $3.21B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $3.04B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $3.07B | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $3.04B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $920.00M | Feb 14, 2020 |
| FY2019 | Aug 31, 2017 | $1.97B | Feb 14, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.41B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.15B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.77B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $872.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $2.73B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $2.06B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $1.07B | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $483.00M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $3.67B | Feb 14, 2020 |
| FY2019 | Aug 31, 2017 | ($3.95B) | Feb 14, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2019 | $1.16B | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $1.50B | Feb 11, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.85B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $40.83B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $43.00B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $42.62B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $42.34B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $42.65B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $42.40B | Feb 11, 2021 |
| FY2020 | Dec 31, 2018 | $108.68B | Feb 11, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.14B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $23.79B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $25.04B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $25.30B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $25.38B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $24.82B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $24.31B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $74.66B | Feb 14, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.47B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $10.41B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $10.61B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $9.96B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $10.11B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $10.27B | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $10.23B | Feb 10, 2022 |
| FY2020 | Jun 1, 2019 | $10.18B | Feb 11, 2021 |
| FY2020 | Dec 31, 2018 | $10.19B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $14.87B | Feb 14, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($67.00M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $55.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | ($41.00M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $250.00M | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $524.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | ($425.00M) | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Feb 14, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.52B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.11B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.64B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $3.19B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $4.46B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $3.53B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.76B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $2.27B | Feb 14, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | (6) | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 14, 2020 |
| FY2019 | Aug 31, 2017 | 2 | Feb 14, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | (6) | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | 1 | Feb 14, 2020 |
| FY2019 | Aug 31, 2017 | 1 | Feb 14, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 672.16M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 685.60M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 701.26M | Feb 12, 2026 |
| FY2025 | Dec 31, 2022 | 713.42M | Feb 12, 2026 |
| FY2024 | Dec 31, 2021 | 726.53M | Feb 14, 2025 |
| FY2023 | Dec 31, 2020 | 743.46M | Feb 8, 2024 |
| FY2022 | Dec 31, 2019 | 748.58M | Feb 9, 2023 |
| FY2021 | Jun 1, 2019 | 748.82M | Feb 10, 2022 |